Latest Articles

Publication Date
[Efficacy and safety of triptorelin acetate microspheres for injection versus triptorelin acetate for injection in Chinese patients with endometriosis: a multicenter, randomized, double-blind, phase Ⅲ non-inferiority clinical trial].

Objective: To evaluate the efficacy and safety of triptorelin acetate microspheres for injection compared with triptorelin acetate for injection in the treatment of endometriosis. Methods: A total of 392 patients …

Published: Jan. 31, 2026, midnight
The effect of tinzaparin sodium and leuprolide acetate in an experimental mouse model of endometriosis: The rol of the WNT/beta-catenin pathway.

Endometriosis is a benign condition driven by estrogen and inflammation in which endometrial-like tissue develops in ectopic locations. We aimed to determine whether non-steroidal agents acting on the WNT/beta-catenin signaling …

Published: Jan. 29, 2026, midnight
Characteristics and Preoperative Management of Adolescent Patients With Pathology-Confirmed Endometriosis: A Multi-Institutional Study.

Endometriosis affects an estimated 25% to 75% of adolescent patients with chronic pelvic pain; the diagnosis is made surgically and treatment typically consists of hormone suppression and pain management strategies. …

Published: Jan. 19, 2026, midnight
Effect of Goserelin acetate on non-invasive indices of hepatic steatosis in women with endometriosis.

Published: Dec. 29, 2025, midnight
Venous Thromboembolism Risk Associated With Relugolix-estradiol-norethisterone Acetate Combination Therapy.

Relugolix, an oral GnRH receptor antagonist, is effective in treating uterine myomas and endometriosis. However, concerns persist regarding the venous thromboembolism (VTE) risk associated with its combination with oral estradiol …

Published: Nov. 22, 2025, midnight
Sterile abscess following intramuscular leuprolide acetate injection for endometriosis: A case report.

Sterile abscess formation after leuprolide acetate (LA) injection is rare and can lead to discomfort, scarring, and decreased treatment efficacy. Our objective is to highlight this rare side effect to …

Published: Nov. 17, 2025, midnight
Safety of 48 months of elagolix with add-back therapy for endometriosis-associated pain.

Elagolix (ELA) 200 mg twice daily is an oral treatment approved for moderate-to-severe endometriosis-associated pain. However, the clinical use of ELA is limited by potential hypoestrogenic effects, including the loss …

Published: Nov. 7, 2025, midnight
Pharmacogenomic analysis of alarelin acetate-induced hepatotoxicity: a case report and literature review.

Alarelin acetate, a synthetic gonadotropin-releasing hormone (GnRH) analogue, is widely used to manage endometriosis and hormone-sensitive malignancies. Although its safety profile is generally favorable, we report the first documented case …

Published: Sept. 29, 2025, midnight
Inguinal endometriosis: a rare entity of a common condition .

A woman in her mid-40s experienced a painful lump in the right groin area for 5 years, with exacerbation during menstruation, coughing and sneezing. Initial treatment with depot methylprednisolone acetate …

Published: Sept. 11, 2025, midnight
Gut Microbiota-Derived Acetate Ameliorates Endometriosis via JAK1/STAT3-Mediated M1 Macrophage Polarisation.

Endometriosis (EMs) is a common inflammatory disorder in women of reproductive age, severely impacting patients' quality of life and fertility. Current hormonal therapies offer limited efficacy, and surgical interventions often …

Published: Aug. 27, 2025, midnight
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!